CD56
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma
Immunophenotypic Characterization of Normal Blood CD56 Versus CD56 NK-Cell Subsets and Its Impact on the Understanding of Their Tissue Distribution and Functional Properties
Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma
Measurements of CD56+ cells in peripheral blood and endometrium by flow cytometry and immunohistochemical staining in situ.
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)
Activation-Induced Expression of CD56 by T Cells Is Associated With a Reprogramming of Cytolytic Activity and Cytokine Secretion Profile
The future is CD56-bright
